drugset / Trial / NCT04509700
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
Timeline
- Start
- 2020-08-03
- Primary completion
- 2026-11-05
- Completion
- 2026-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 140 mg | — |
| Subject | Itacitinib | Small molecule | 100 mg | — |
| Subject | Parsaclisib | Unknown | 1 mg | — |
| Subject | Parsaclisib | Unknown | 2.5 mg | — |
| Subject | Parsaclisib | Unknown | 5 mg | — |
| Subject | Parsaclisib | Unknown | 20 mg | — |
| Subject | Ruxolitinib | Small molecule | — | — |